A recent study found that 92 percent of people with relapsing multiple sclerosis (MS) who took ublituximab (Briumvi) for five years had no confirmed disability worsening.

🗳️ Have you tried a disease-modifying therapy (DMT) to help prevent MS relapses?

Yes, and it worked well for me.

Yes, but it did not work as well as I’d like.

No, but I’m interested in learning more about DMTs.

No, and I’m not interested.

Thanks! You've successfully submitted your vote.

Sign up to view the results!

Continue with Facebook

Continue with Google

Continue with Email

By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data and Privacy policies.

Already a member? Log In

Over time, MS can affect mobility, thinking, and daily activities. A treatment that helps slow disability progression over several years may help people with MS maintain independence and quality of life longer.

What Is Ublituximab?

Ublituximab is a disease-modifying therapy (DMT) approved to treat relapsing forms of MS, in which symptoms flare up and then improve.

Ublituximab is part of a group of MS treatments called anti-CD20 therapies. This group also includes biologic medications like ocrelizumab (Ocrevus) and ofatumumab (Kesimpta). These drugs are thought to work by targeting and reducing B cells, which play a role in MS inflammation and attacks.

Ublituximab is given as an intravenous (into a vein) infusion, typically every six months after the initial doses.

The medication was approved in the U.S. in 2022. Like ocrelizumab and ofatumumab, it is considered a high-efficacy treatment, meaning it can significantly reduce disease activity.

Inside the Study: 5 Years of Data

This study followed 851 adults with relapsing MS who either remained on ublituximab or switched to it after taking another MS drug. Researchers tracked outcomes for up to five years.

Here are some of the key findings:

• After five years, 92 percent of those continuously taking ublituximab had no confirmed disability worsening.
• By 5 years, relapses were rare among people taking ublituximab.
• People who began ublituximab earlier had a lower risk of disability progression than those who switched later.
• About 17 percent of people on continuous treatment experienced confirmed disability improvement, compared with 12.2 percent who switched later.

Side Effects and Safety Considerations

Common or notable side effects of ublituximab included:

• Infusion-related reactions (such as chills, fever, or headache)
• Infections, including respiratory infections

Serious infections were relatively uncommon, occurring at a rate of about 2 to 2.6 cases per 100 person-years (about two to three cases per 100 people per year).

What This Means for People Living With MS

This study adds to evidence that long-term treatment with high-efficacy therapies may help reduce relapses and slow disability progression.

For people living with MS, these findings highlight a few important benefits of high-efficacy DMTs, such as:

• Long-term treatment may offer lasting benefits.
• Starting an effective therapy earlier may influence outcomes.
• Some people may even see improvements over time.

At the same time, treatment decisions are personal. MS affects everyone differently, and factors like side effects, lifestyle, and other health conditions all play a role in choosing a therapy.

If you’re living with MS, you might want to talk with your neurologist about the potential benefits and risks of different treatment options.

Join the Conversation

On MyMSTeam, people living with MS share their experiences with symptoms, treatments, and daily life with the condition.

Which medications have you used to prevent MS relapses? What has your experience been like? Share your thoughts in the comments below.